Mohamad Issa, Abu-Hijleh Fawzi, Mayta Ebrahim, Abu-Hejleh Taher, Al-Gargaz Wisam, Al Mousa Abdellatif, Abu-Hijlih Ramiz, Hosni Ali
Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Department of Surgical Oncology, King Hussein Cancer Center, Amman, Jordan.
South Asian J Cancer. 2022 Feb 27;11(3):223-228. doi: 10.1055/s-0042-1742724. eCollection 2022 Jul.
Issa Mohamad To compare outcomes and toxicity of two standard treatment approaches of advanced nasopharyngeal carcinoma (NPC). Between 2010 and 2016, patients with NPC, stage II-IVa, treated with induction chemotherapy (IC) (TPF), followed by concurrent chemoradiotherapy (CCRT) (induction group), or CCRT, followed by adjuvant chemotherapy (AC) (PF) (no-induction group), were retrospectively reviewed. CCRT included platinum-based chemotherapy with intensity-modulated radiotherapy. Survival outcomes, the pattern of failures, toxicity, and predictors for survival outcomes were evaluated. A total of 110 patients were included, 65 in the induction group and 45 in the no-induction group. There were no significant differences in the DFS and overall survival (OS) at 3 years between the two groups. On multivariate analysis, performance status (1 vs. 0) predicted worse OS. The 3-year cumulative incidence rates for local, regional, and distant failures were 58.5% (95% confidence interval [CI]: 8.4-89%), 58.00% (95% CI: 8-88.8%), and 63.90% (95% CI: 14.1-90.2%), respectively. IC had more frequent acute grade (G) II anemia (13 vs. 1, < 0.01), late G II brain toxicity (4 vs. 1, < 0.01), and late G II dysphagia (32 vs. 11, = 0.01). Survival outcomes were comparable between the two groups. IC had more frequent acute G II anemia and late G II brain and esophageal toxicities.
伊萨·穆罕默德 比较晚期鼻咽癌（NPC）两种标准治疗方法的疗效和毒性。 在2010年至2016年期间，对II-IVa期NPC患者进行回顾性研究，这些患者接受诱导化疗（IC）（TPF方案），随后进行同步放化疗（CCRT）（诱导组），或接受CCRT，随后进行辅助化疗（AC）（PF方案）（非诱导组）。CCRT包括铂类化疗联合调强放疗。评估生存结局、失败模式、毒性以及生存结局的预测因素。 共纳入110例患者，诱导组65例，非诱导组45例。两组3年无病生存期（DFS）和总生存期（OS）无显著差异。多因素分析显示，体能状态（1 vs. 0）是OS较差的预测因素。局部、区域和远处失败的3年累积发生率分别为58.5%（95%置信区间[CI]：8.4-89%）、58.00%（95% CI：8-88.8%）和63.90%（95% CI：14.1-90.2%）。IC组急性II级贫血（13例 vs. 1例，P<0.01）、晚期II级脑毒性（4例 vs. 1例，P<0.01）和晚期II级吞咽困难（32例 vs. 11例，P=0.01）更为常见。 两组生存结局相当。IC组急性II级贫血以及晚期II级脑和食管毒性更为常见。
